Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 18, 2012 09:30 ET | Source: TapImmune Inc.

TapImmune to Open New Laboratories and Offices at 1551 Eastlake Ave.

SEATTLE, Jan. 18, 2012 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) has signed a sub-lease for newly-renovated, state of the art laboratory and office space at 1551 Eastlake Avenue in South Lake...
November 22, 2011 09:30 ET | Source: TapImmune Inc.

TapImmune Appoints Mark Reddish to Its Management Team as Vice President Product Development

SEATTLE, Nov. 22, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), is pleased to announce that Mark Reddish has joined its Management Team as Vice President of Product Development. Mark was...
November 02, 2011 09:35 ET | Source: TapImmune Inc.

TapImmune Inc. to Collaborate With Nature Immunology and Arkitek Studios

SEATTLE, Nov. 2, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) is pleased to announce a collaboration with Nature Immunology and Arkitek Studios to visualize TAP's role in combating...
October 31, 2011 09:25 ET | Source: TapImmune Inc.

TapImmune Inc. and Aeras Start Research & Development Collaboration

SEATTLE, Oct. 31, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) announced that it has signed a Research Collaboration with Aeras. The overall goal of this collaboration will be to evaluate the...
October 27, 2011 09:35 ET | Source: TapImmune Inc.

TapImmune Inc. Announces Issuance of US Patent

SEATTLE, Oct. 27, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) announced that the US Patent Office has issued Patent 7,994,146 entitled "Method of Enhancing an Immune Response". The...
October 21, 2011 16:00 ET | Source: TapImmune Inc.

TapImmune to Present at BIT's 2nd Annual World Congress on Immunodiseases and Therapy in Guangzhou, China, November 18, 2011

SEATTLE, Oct. 21, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a biotechnology company developing immunotherapies, today announced that its Chairman and CEO, Dr. Glynn Wilson, is an invited...
August 11, 2011 16:19 ET | Source: TapImmune Inc.

TapImmune to Sponsor Phase 1 Breast Cancer Vaccine Trial Following Recent FDA Approval of Investigational New Drug Application

SEATTLE and ROCHESTER, Minn., Aug. 11, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a leading biotechnology company developing immunotherapies, today announced that following FDA IND...
April 28, 2011 09:45 ET | Source: TapImmune Inc.

TapImmune Inc to Present at Aegis Capital Emerging Growth Conference in Las Vegas on April 30, 2011

SEATTLE, April 28, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), a biotechnology company specializing in the development of immunotherapeutics and vaccines in the areas of oncology and...
April 07, 2011 10:42 ET | Source: TapImmune Inc.

TapImmune Receives Notice of Allowance for U.S. Patent Application Relating to Vaccines Containing TAP for the Treatment of Pox Virus Infections

SEATTLE, April 7, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV) announced today that the U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. patent application...
April 05, 2011 09:20 ET | Source: TapImmune Inc.

TapImmune Provides Corporate Update

SEATTLE, April 5, 2011 (GLOBE NEWSWIRE) -- TapImmune Inc. (OTCBB:TPIV), is pleased to provide this corporate update to our current and future shareholders and other interested parties. Our...